MDS clinical diagnostic criteria for Parkinson's disease

Movement DisordersVolume 30, Issue 12 p. 1591-1601 Review MDS clinical diagnostic criteria for Parkinson's disease Ronald B. Postuma MD, MSc, Corresponding Author Ronald B. Postuma MD, MSc Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada Contributed equally.Correspondence to: Dr. Daniela Berg, Hertie Institute of Clinical Brain Research, Hoppe, Seyler-Straße 3, 72076 Tubingen, Germany; Daniela.berg@uni-tueb, or Dr. Ronald B. Postuma, Department of Neurology, L7-305 Montreal General Hospital, 1650 Cedar Avenue, Montreal, Canada H3G1A4, E-mail: [email protected]Search for more papers by this authorDaniela Berg MD, Corresponding Author Daniela Berg MD Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany Contributed equally.Correspondence to: Dr. Daniela Berg, Hertie Institute of Clinical Brain Research, Hoppe, Seyler-Straße 3, 72076 Tubingen, Germany; Daniela.berg@uni-tueb, or Dr. Ronald B. Postuma, Department of Neurology, L7-305 Montreal General Hospital, 1650 Cedar Avenue, Montreal, Canada H3G1A4, E-mail: [email protected]Search for more papers by this authorMatthew Stern MD, Matthew Stern MD Penn Neurological Institute, Philadelphia, Pennsylvania, USASearch for more papers by this authorWerner Poewe MD, Werner Poewe MD Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaSearch for more papers by this authorC. Warren Olanow MD, FRCPC, C. Warren Olanow MD, FRCPC Department of Neurology, The Mount Sinai Hospital, New York, New York, USASearch for more papers by this authorWolfgang Oertel MD, Wolfgang Oertel MD Department of Neurology, Philipps University of Marburg, Marburg, GermanySearch for more papers by this authorJosé Obeso MD, PhD, José Obeso MD, PhD University of Navarra-FIMA, Pamplona, SpainSearch for more papers by this authorKenneth Marek MD, Kenneth Marek MD Institute for Neurodegenerative Disorders, New Haven, Connecticut, USASearch for more papers by this authorIrene Litvan MD, Irene Litvan MD Department of Neurosciences, UC San Diego, La Jolla, California, USASearch for more papers by this authorAnthony E. Lang OC, MD, FRCPC, Anthony E. Lang OC, MD, FRCPC Division of Neurology, Toronto Western Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorGlenda Halliday PhD, Glenda Halliday PhD Neuroscience Research Australia & University of NSW, Randwick, AustraliaSearch for more papers by this authorChristopher G. Goetz MD, Christopher G. Goetz MD Rush University Medical Center, Chicago, Illinois, USASearch for more papers by this authorThomas Gasser MD, Thomas Gasser MD Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, GermanySearch for more papers by this authorBruno Dubois MD, PhD, Bruno Dubois MD, PhD Hopital De La Salpetriere, Paris, FranceSearch for more papers by this authorPiu Chan MD, PhD, Piu Chan MD, PhD Xuanwu Hospital of Capitol of Medical University, Beijing, Peoples Republic of ChinaSearch for more papers by this authorBastiaan R. Bloem MD, PhD, Bastiaan R. Bloem MD, PhD Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, NetherlandsSearch for more papers by this authorCharles H. Adler MD, PhD, Charles H. Adler MD, PhD The Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USASearch for more papers by this authorGünther Deuschl MD, Günther Deuschl MD Department of Neurology, Christian-Albrechts University, Kiel, GermanySearch for more papers by this author Ronald B. Postuma MD, MSc, Corresponding Author Ronald B. Postuma MD, MSc Department of Neurology, Montreal General Hospital, Montreal, Quebec, Canada Contributed equally.Correspondence to: Dr. Daniela Berg, Hertie Institute of Clinical Brain Research, Hoppe, Seyler-Straße 3, 72076 Tubingen, Germany; Daniela.berg@uni-tueb, or Dr. Ronald B. Postuma, Department of Neurology, L7-305 Montreal General Hospital, 1650 Cedar Avenue, Montreal, Canada H3G1A4, E-mail: [email protected]Search for more papers by this authorDaniela Berg MD, Corresponding Author Daniela Berg MD Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, Germany Contributed equally.Correspondence to: Dr. Daniela Berg, Hertie Institute of Clinical Brain Research, Hoppe, Seyler-Straße 3, 72076 Tubingen, Germany; Daniela.berg@uni-tueb, or Dr. Ronald B. Postuma, Department of Neurology, L7-305 Montreal General Hospital, 1650 Cedar Avenue, Montreal, Canada H3G1A4, E-mail: [email protected]Search for more papers by this authorMatthew Stern MD, Matthew Stern MD Penn Neurological Institute, Philadelphia, Pennsylvania, USASearch for more papers by this authorWerner Poewe MD, Werner Poewe MD Department of Neurology, Innsbruck Medical University, Innsbruck, AustriaSearch for more papers by this authorC. Warren Olanow MD, FRCPC, C. Warren Olanow MD, FRCPC Department of Neurology, The Mount Sinai Hospital, New York, New York, USASearch for more papers by this authorWolfgang Oertel MD, Wolfgang Oertel MD Department of Neurology, Philipps University of Marburg, Marburg, GermanySearch for more papers by this authorJosé Obeso MD, PhD, José Obeso MD, PhD University of Navarra-FIMA, Pamplona, SpainSearch for more papers by this authorKenneth Marek MD, Kenneth Marek MD Institute for Neurodegenerative Disorders, New Haven, Connecticut, USASearch for more papers by this authorIrene Litvan MD, Irene Litvan MD Department of Neurosciences, UC San Diego, La Jolla, California, USASearch for more papers by this authorAnthony E. Lang OC, MD, FRCPC, Anthony E. Lang OC, MD, FRCPC Division of Neurology, Toronto Western Hospital, Toronto, Ontario, CanadaSearch for more papers by this authorGlenda Halliday PhD, Glenda Halliday PhD Neuroscience Research Australia & University of NSW, Randwick, AustraliaSearch for more papers by this authorChristopher G. Goetz MD, Christopher G. Goetz MD Rush University Medical Center, Chicago, Illinois, USASearch for more papers by this authorThomas Gasser MD, Thomas Gasser MD Department of Neurodegeneration, Hertie-Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, Tuebingen, GermanySearch for more papers by this authorBruno Dubois MD, PhD, Bruno Dubois MD, PhD Hopital De La Salpetriere, Paris, FranceSearch for more papers by this authorPiu Chan MD, PhD, Piu Chan MD, PhD Xuanwu Hospital of Capitol of Medical University, Beijing, Peoples Republic of ChinaSearch for more papers by this authorBastiaan R. Bloem MD, PhD, Bastiaan R. Bloem MD, PhD Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, NetherlandsSearch for more papers by this authorCharles H. Adler MD, PhD, Charles H. Adler MD, PhD The Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USASearch for more papers by this authorGünther Deuschl MD, Günther Deuschl MD Department of Neurology, Christian-Albrechts University, Kiel, GermanySearch for more papers by this author First published: 16 October 2015 https://doi.org/10.1002/mds.26424Citations: 3,393 Funding agencies: This study was supported by the work of the task force – i.e. meetings and tele-conferences – were supported by the MDS. Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract This document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances. © 2015 International Parkinson and Movement Disorder Society References 1 Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014; 29: 454–462. 2 Berg D, Postuma RB, Adler CH, et al. MDS Research Criteria for Prodromal Parkinson's Disease. Mov Disord 2015. 3 Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–752. 4 Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992; 32(Suppl): S125–S127. 5 Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33–39. 6 Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467–486. 7 Berg D, Lang AE, Postuma RB, et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013; 12: 514–524. 8 Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991; 18: 275–278. 9 Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497–1499. 10 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184. 11 Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75–86. 12 Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55: 969–978. 13 Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014; 83: 406–412. 14 Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861–870. 15 Kollensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008; 23: 1093–1099. 16 McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–1872. 17 Shah M, Muhammed N, Findley LJ, Hawkes CH. Olfactory tests in the diagnosis of essential tremor. Parkinsonism Relat Disord 2008; 14: 563–568. 18 Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995; 91: 247–250. 19 Muller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci 2002; 9: 521–524. 20 Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008; 14: 600–607. 21 Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ. Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1749–1752. 22 Kikuchi A, Baba T, Hasegawa T, Sugeno N, Konno M, Takeda A. Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism Relat Disord 2011; 17: 698–700. 23 Suzuki M, Hashimoto M, Yoshioka M, Murakami M, Kawasaki K, Urashima M. The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy. BMC Neurol 2011; 11: 157. 24 Busse K, Heilmann R, Kleinschmidt S, et al. Value of combined midbrain sonography, olfactory and motor function assessment in the differential diagnosis of early Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83: 441–447. 25 Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis. Behav Brain Res 2012; 231: 60–74. 26 Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord 2012; 18: 494–500. 27 Yoshita M, Hayashi M, Hirai S. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy]. Rinsho Shinkeigaku 1997; 37: 476–482. 28 Shin DH, Lee PH, Bang OY, Joo IS, Huh K. Clinical implications of cardiac-MIBG SPECT in the differentiation of Parkinsonian syndromes. J Clin Neurol 2006; 2: 51–57. 29 Kashihara K, Ohno M, Kawada S, Okumura Y. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 2006; 47: 1099–1101. 30 Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–2170. 31 Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456–2477. 32 Gilman S, Lost D, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–676. Citing Literature Volume30, Issue12October 2015Pages 1591-1601 ReferencesRelatedInformation